Literature DB >> 7351765

Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence.

B L Riggs, S F Hodgson, D L Hoffman, P J Kelly, K A Johnson, D Taves.   

Abstract

Thirty-six patients with primary osteoporosis were treated for up to six years with sodium fluoride, calcium supplements, and, in 24 patients, vitamin D. Major adverse reactions (synovitis, painful plantar fascial syndrome, recurrent vomiting, or anemia) occurred in 15 patients (42%). New vertebral fractures occurred at a rate of 329 fractures per 1,000 years of observation. Almost half of them occurred during the first year of therapy, and they were only one sixth as frequent in 12 patients who had fluoride-induced increased trabeculation on vertebral roentogenograms. Nevertheless, until long-term safety and antifracture efficacy are better established, this regimen should continue to be restricted to investigational use.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351765

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  23 in total

1.  Substituted hydroxyapatites for bone repair.

Authors:  Jennifer H Shepherd; David V Shepherd; Serena M Best
Journal:  J Mater Sci Mater Med       Date:  2012-03-03       Impact factor: 3.896

2.  The increase in spinal bone density that occurs in response to fluoride therapy for osteoporosis is not maintained after the therapy is discontinued.

Authors:  J R Talbot; M M Fischer; S M Farley; C Libanati; J Farley; A Tabuenca; D J Baylink
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

Review 3.  Phosphotyrosyl protein phosphatases.

Authors:  K H Lau; J R Farley; D J Baylink
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

4.  Gastroduodenal manifestations in patients with skeletal fluorosis.

Authors:  S Dasarathy; T K Das; I P Gupta; A K Susheela; R K Tandon
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

5.  Tissue response of gastric mucosa after ingestion of fluoride.

Authors:  C J Spak; S Sjöstedt; L Eleborg; B Veress; L Perbeck; J Ekstrand
Journal:  BMJ       Date:  1989-06-24

6.  Comparison of the radiographic vertebral trabecular pattern with the vertebral fracture prevalence and spinal bone density.

Authors:  C M Schnitzler; D G Pitchford; E M Willis; K A Gear
Journal:  Osteoporos Int       Date:  1993-12       Impact factor: 4.507

Review 7.  Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action.

Authors:  B A Dure-Smith; M E Kraenzlin; S M Farley; C R Libanati; E E Schulz; D J Baylink
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 8.  Fluoride therapy of type I osteoporosis.

Authors:  J P Devogelaer; C Nagant de Deuxchaisnes
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

Review 9.  Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.

Authors:  T M Murray; L G Ste-Marie
Journal:  CMAJ       Date:  1996-10-01       Impact factor: 8.262

Review 10.  Hip fracture, skeletal fragility, osteoporosis and hormonal deprivation in elderly women.

Authors:  E E Specht
Journal:  West J Med       Date:  1980-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.